Anteris Technologies Global Corp

AVR

5.115USD

-0.275-5.10%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

Anteris Technologies Global Corp's Score

Industry at a Glance

Industry Ranking

111 / 208

Overall Ranking

263 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Anteris Technologies Global Corp Highlights

StrengthsRisks

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.91M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.91M.

Overvalued

The company’s latest PE is -2.03, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 25.19M shares, increasing 5.38% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 2.04K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

15.200

Target Price

+182.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Anteris Technologies Global Corp is 5.14, ranking 205 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 310.00K, representing a year-over-year decrease of 42.18%, while its net profit experienced a year-over-year decrease of 50.72%.

Score

Industry at a Glance

Previous score

5.14

Change

0



Financials

6.09

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

2.78

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Anteris Technologies Global Corp is 7.95, ranking 50 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -2.03, which is -29.04% below the recent high of -1.44 and -100.37% above the recent low of -4.08.

Score

Industry at a Glance

Previous score

7.95

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 111/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Anteris Technologies Global Corp is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 17.50, with a high of 22.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Anteris Technologies Global Corp is 6.44, ranking 130 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 6.38 and the support level at 4.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.51

Change

-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Anteris Technologies Global Corp is 5.00, ranking 114 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 56.54%, representing a quarter-over-quarter increase of 5.86%. The largest institutional shareholder is The Vanguard, holding a total of 841.34K shares, representing 0.87% of shares outstanding, with 242.15% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

L1 Capital Pty Ltd.

8.22M

+20.21%

Nantahala Capital Management, LLC

1.92M

+13.28%

Sio Capital Management, LLC

1.77M

-3.61%

BlackRock Institutional Trust Company, N.A.

1.72M

+85.12%

Perceptive Advisors LLC

1.71M

--

Ensign Peak Advisors, Inc.

1.41M

-2.28%

J.P. Morgan Securities LLC

1.40M

+32.71%

Adar1 Capital Management LLC

197.62K

-62.82%

Rhenman & Partners Asset Management AB

1.25M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Anteris Technologies Global Corp is 1.99, ranking 168 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Anteris Technologies Global Corp

AVR

6.06 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment